Literature DB >> 18184821

Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.

Lin Lin1, Ashraf S Ibrahim, Valentina Avanesian, John E Edwards, Yue Fu, Beverlie Baquir, Rebecca Taub, Brad Spellberg.   

Abstract

We are developing an anticandidal vaccine using the recombinant N terminus of Als3p (rAls3p-N). We report that although more rAls3p-N was bound by aluminum hydroxide diluted in saline than by aluminum hydroxide diluted in phosphate-buffered saline (PBS), its immunogenicity and efficacy were superior in PBS. Thus, protein binding, by itself, may not predict the efficacy of some vaccines with aluminum adjuvants.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18184821      PMCID： PMC2268268          DOI： 10.1128/CVI.00427-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  18 in total

1.  Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits.

Authors:  M Chang; Y Shi; S L Nail; H HogenEsch; S B Adams; J L White; S L Hem
Journal:  Vaccine       Date:  2001-04-06       Impact factor: 3.641

Review 2.  Aluminium adjuvants--in retrospect and prospect.

Authors:  Erik B Lindblad
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

3.  Predicting the adsorption of proteins by aluminium-containing adjuvants.

Authors:  S J Seeber; J L White; S L Hem
Journal:  Vaccine       Date:  1991-03       Impact factor: 3.641

4.  Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response.

Authors:  Bethany Hansen; Anna Sokolovska; Harm HogenEsch; Stanley L Hem
Journal:  Vaccine       Date:  2007-07-16       Impact factor: 3.641

5.  Quaternary structure of the Mr 46,000 mannose 6-phosphate specific receptor: effect of ligand, pH, and receptor concentration on the equilibrium between dimeric and tetrameric receptor forms.

Authors:  A Waheed; A Hille; U Junghans; K von Figura
Journal:  Biochemistry       Date:  1990-03-13       Impact factor: 3.162

6.  Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis.

Authors:  Brad Spellberg; Douglas Johnston; Quynh Trang Phan; John E Edwards; Samuel W French; Ashraf S Ibrahim; Scott G Filler
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

Review 7.  Aluminium compounds for use in vaccines.

Authors:  Erik B Lindblad
Journal:  Immunol Cell Biol       Date:  2004-10       Impact factor: 5.126

Review 8.  Adjuvants--a balance between toxicity and adjuvanticity.

Authors:  R K Gupta; E H Relyveld; E B Lindblad; B Bizzini; S Ben-Efraim; C K Gupta
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

9.  Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens.

Authors:  L M Flebbe; H Braley-Mullen
Journal:  Cell Immunol       Date:  1986-04-15       Impact factor: 4.868

10.  Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine.

Authors:  Güler Kanra; Simonetta Viviani; Kadriye Yurdakök; Elif Ozmert; Alessandra Anemona; Songül Yalçin; Okan Demiralp; Nihan Bilgili; Ates Kara; Ali Bülent Cengiz; Belgin Mutlu; Alexandra Baldini; Elisa Marchetti; Audino Podda
Journal:  Pediatr Int       Date:  2003-06       Impact factor: 1.524
View more
  10 in total

Review 1.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

2.  Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions.

Authors:  Allan Watkinson; Andrei Soliakov; Ashok Ganesan; Karie Hirst; Chris Lebutt; Kelly Fleetwood; Peter C Fusco; Thomas R Fuerst; Jeremy H Lakey
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

3.  Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus.

Authors:  Lin Lin; Ashraf S Ibrahim; Beverlie Baquir; Valentina Avanesian; Yue Fu; Brad Spellberg
Journal:  FEMS Immunol Med Microbiol       Date:  2009-01-13

4.  Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein.

Authors:  Beverlie Baquir; Lin Lin; Ashraf S Ibrahim; Yue Fu; Valentina Avanesian; Ang Tu; John Edwards; Brad Spellberg
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

5.  Vaccines for invasive fungal infections.

Authors:  Brad Spellberg
Journal:  F1000 Med Rep       Date:  2011-07-01

6.  NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice.

Authors:  Abdullah Alqarihi; Shakti Singh; John E Edwards; Ashraf S Ibrahim; Priya Uppuluri
Journal:  Sci Rep       Date:  2019-04-17       Impact factor: 4.379

Review 7.  Advances in Fungal Peptide Vaccines.

Authors:  Leandro B R Da Silva; Carlos P Taborda; Joshua D Nosanchuk
Journal:  J Fungi (Basel)       Date:  2020-07-25

8.  Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.

Authors:  Lin Lin; Ashraf S Ibrahim; Xin Xu; Joshua M Farber; Valentina Avanesian; Beverlie Baquir; Yue Fu; Samuel W French; John E Edwards; Brad Spellberg
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823

9.  Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis.

Authors:  Priya Uppuluri; Shakti Singh; Abdullah Alqarihi; Clint S Schmidt; John P Hennessey; Michael R Yeaman; Scott G Filler; John E Edwards; Ashraf S Ibrahim
Journal:  Front Immunol       Date:  2018-06-15       Impact factor: 7.561

Review 10.  Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action.

Authors:  Emma Shardlow; Matthew Mold; Christopher Exley
Journal:  Allergy Asthma Clin Immunol       Date:  2018-11-07       Impact factor: 3.406
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.